Download PDF
Z Gastroenterol 2017; 55(07): 685-686
DOI: 10.1055/s-0043-106861
Kommentiertes Referat
© Georg Thieme Verlag KG Stuttgart · New York

Regorafenib – Revolution der systemischen Therapieoptionen beim HCC?

Regorafenib – a revolution in the systemic treatment options of HCC?
Jan Bornschein
,
Sophie Schlosser
Further Information

Publication History

Publication Date:
24 April 2017 (online)

Also available at
    Permissions and Reprints

Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2017, 389: 56 – 66